Kodiak Sciences Inc
KODDrugs in Pipeline
5
Phase 3 Programs
5
Upcoming Catalysts
3
Next Catalyst
Aug 12, 2026
7dMarket Overview
Stock performance and key metrics
3 upcoming, 0 past
KOD Earnings Report
EPS Est: $-0.97 | FQ end 2026-06
Aflibercept Phase 3 Est. Readout
Primary completion for Aflibercept trial (NCT06556368) in Wet Age-related Macular Degeneration
Source1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How KOD's past catalysts played out
KSI-101
Macular Edema Secondary to Inflammation
KSI-301
Macular Edema
Tarcocimab
Diabetic Retinopathy
Tarcocimab tedromer
Wet Age-related Macular Degeneration
Aflibercept
Wet Age-related Macular Degeneration
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
KSI-101 | Phase 3 | Macular Edema Secondary to Inflammation | - | - |
KSI-301 | Phase 3 | Macular Edema | - | - |
Tarcocimab | Phase 3 | Diabetic Retinopathy | - | - |
Tarcocimab tedromer | Phase 3 | Wet Age-related Macular Degeneration | - | - |
Aflibercept | Phase 3 | Wet Age-related Macular Degeneration | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Kodiak Sciences Inc's drug pipeline?→
CatalystAlert tracks 5 drug candidates in Kodiak Sciences Inc's (KOD) pipeline across Phase 3. Its lead program is KSI-101 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Kodiak Sciences Inc's next FDA catalyst?→
Kodiak Sciences Inc's (KOD) next tracked catalyst is a Earnings expected August 12, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track KOD biotech catalysts?→
Add KOD to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Kodiak Sciences Inc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.